IBOPNCT07923877
Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Patients receive induction therapy with carboplatin, paclitaxel IV and pembrolizumab IV over 30 minutes every 3 weeks for up to 2-3 cycles. After induction, patients undergo standard of care laryngectomy followed by adjuvant RT and chemotherapy if indicated. Additionally, patients undergo blood and drain fluid sample collection, CT, and PET/CT throughout the study.
Patients receive induction therapy with carboplatin, paclitaxel IV and pembrolizumab IV over 30 minutes every 3 weeks for up to 2-3 cycles. After induction, patients undergo IMRT or intensity modulated proton therapy QD on Monday-Friday weekly for up to 18 treatment fractions. Patient may also receive cisplatin IV over 30 minutes to 4 hours weekly during radiation therapy. Additionally, patients undergo blood sample collection, CT, and PET/CT throughout the study.
Procedures: Biospecimen Collection, Computed Tomography, Intensity-Modulated Proton Therapy, Laryngectomy, Positron Emission Tomography
Drugs: Carboplatin, Chemotherapy, Cisplatin, Paclitaxel
Other: Electronic Health Record Review, Questionnaire Administration
Radiation: Intensity-Modulated Radiation Therapy, Radiation Therapy
Biologicals: Pembrolizumab
Sites
1 site in 1 country
- Mayo Clinic in RochesterRochester, Minnesota, United States